Bio-Techne Corp
NASDAQ:TECH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bio-Techne Corp
NASDAQ:TECH
|
US |
|
Matador Partners Group AG
F:SQL
|
CH |
Intrinsic Value
The intrinsic value of Bio-Techne Corp (TECH) under the Base Case is 58.72 USD per share.
Compared with the current market price of 72.49 USD, the stock appears
Overvalued by 19% .
The intrinsic value is calculated using the DCF method. The model assumes operating margin rises from 23% last year to 33% by 2033, higher than in any of the last six years. If operating margin stayed at its five-year average of 24%, the estimate would be about $43.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Bio-Techne Does
Bio-Techne makes the tools scientists use to study cells and disease. Its products include antibodies, proteins, assays, cell and gene therapy reagents, and instruments used in life-science research and clinical testing. The company also sells diagnostic products that help labs detect and monitor certain medical conditions.
- Headquarters
- United States of America US
- Employees
- 3 100
- IPO date
- Feb 9, 1989
Revenue & Expenses Breakdown
Bio-Techne Corp
Earnings Waterfall
Bio-Techne Corp
The intrinsic value for Bio-Techne Corp (TECH) under the Base Case is 58.72 USD.
Compared with the current market price of 72.49 USD, the stock appears Overvalued by 19% .